Atara biotherapeutics announces second quarter 2023 financial results and operational progress

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, recent business highlights and key upcoming catalysts. “we are pleased to announce ind clearance for ata3219, our first allogeneic car-t cell product candidate.
ATRA Ratings Summary
ATRA Quant Ranking